InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | 2026-05-13 | Chernett Jorey | 10% Owner | Purchase | 475.0K | $1.34 | $637K | 10.45M | View ↗ | |
| 2026-04-21 | 2026-04-22 | Chernett Jorey | 10% Owner | Purchase | 100.0K | $1.51 | $151K | 9.98M | View ↗ | |
| 2026-04-20 | 2026-04-22 | Chernett Jorey | 10% Owner | Purchase | 100.0K | $1.58 | $158K | 9.88M | View ↗ | |
| 2026-03-30 | 2026-03-30 | Chernett Jorey | 10% Owner | Purchase | 385.4K | $1.25 | $482K | 9.78M | View ↗ | |
| 2026-03-27 | 2026-03-30 | Chernett Jorey | 10% Owner | Purchase | 500.0K | $1.35 | $675K | 9.39M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Revenues | $87.0M+1856.7% | $4.4M-93.8% | $71.3M+9.4% | $65.2M+17.9% | $55.3M |
| Total Cost of revenues | $60.4M+1779.4% | $3.2M-83.6% | $19.6M+26.9% | $15.5M+32.9% | $11.7M |
| Gross profit | $72.3M+33.5% | $54.2M+4.8% | $51.7M+4.0% | $49.7M+13.9% | $43.7M |
| Sales and marketing | $47.5M+4.0% | $45.6M-3.6% | $47.3M-5.3% | $50.0M+32.4% | $37.7M |
| General and administrative | $49.7M+63.9% | $30.3M+19.3% | $25.4M-0.4% | $25.5M-0.1% | $25.6M |
| Research and development | $6.6M-48.4% | $12.8M+34.2% | $9.5M+1.9% | $9.3M+17.8% | $7.9M |
| Total operating expenses | $103.7M+16.9% | $88.7M+7.9% | $82.3M-3.0% | $84.8M+19.1% | $71.2M |
| Loss from operations | -$31.4M+9.0% | -$34.6M-13.1% | -$30.6M+13.0% | -$35.1M-27.4% | -$27.6M |
| Interest expense | $8.4M+15.5% | $7.3M+34.3% | $5.4M+27.6% | $4.3M+5.8% | $4.0M |
| Loss on extinguishment of debt | $4.4M | — | — | — | — |
| Other income, net | -$716K+71.9% | -$2.5M+56.0% | -$5.8M-162.8% | -$2.2M-464.9% | -$390K |
| Net loss | -$39.1M+10.5% | -$43.7M-44.8% | -$30.2M+18.8% | -$37.2M-19.1% | -$31.2M |
| Less: Net loss attributable to non-controlling interest | -$137K-621.1% | -$19K | — | — | — |
| Net loss attributable to Neuronetics stockholders' | -$39.0M+10.8% | -$43.7M-44.8% | -$30.2M+18.8% | -$37.2M-19.1% | -$31.2M |
| Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders' | -$590+57.2% | -$1K-31.4% | -$1K+23.9% | -$1K-13.1% | -$1K |
| Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders' | -$590+57.2% | -$1K-31.4% | -$1K+23.9% | -$1K-13.1% | -$1K |
| Weighted average common shares outstanding, basic (in shares) | $66.0M+107.8% | $31.7M+10.7% | $28.7M+6.5% | $26.9M+5.6% | $25.5M |
| Weighted average common shares outstanding, diluted (in shares) | $66.0M+107.8% | $31.7M+10.7% | $28.7M+6.5% | $26.9M+5.6% | $25.5M |
| Products and Other | |||||
| Services | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
Neuronetics Q1 Earnings Call Highlights
Neuronetics, Inc. Q1 2026 Earnings Call Summary
Neuronetics (STIM) Q1 2026 Earnings Transcript